Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 5/20 | 0.95 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.95 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.95 |
| ▸ | MYLK | Q15746 | 3/20 | 0.95 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.95 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.95 |
| ▸ | MEN1 | O00255 | 3/20 | 0.95 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.95 |
| ▸ | TP53 | P04637 | 2/20 | 0.95 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.95 |
| ▸ | LMNA | P02545 | 3/20 | 0.92 |
| ▸ | GMNN | O75496 | 2/20 | 0.92 |
| ▸ | MAPT | P10636 | 2/20 | 0.92 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.92 |
| ▸ | ROCK1 | Q13464 | 5/20 | 0.70 |
| ▸ | TSHR | P16473 | 3/20 | 0.70 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.70 |
| ▸ | MTOR | P42345 | 1/20 | 0.70 |
| ▸ | RAB9A | P51151 | 1/20 | 0.70 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2869228 | 0.97 | CYP3A4 (1.00) | CYP3A4KMT2ACYP2D6MYLKNFKB1 | |
| Hydrochloric Acid SCHEMBL1848494 | 0.96 | MAPK1 (1.00) | CYP3A4KMT2ACYP2D6MYLKNFKB1 | |
| Hydrochloric Acid SCHEMBL29370764 | 0.96 | MAPK1 (1.00) | CYP3A4KMT2ACYP2D6MYLKNFKB1 | |
| Hydrochloric Acid SCHEMBL1981350 | 0.86 | ROCK1 (0.95) | CYP3A4KMT2ACYP2D6MYLKNFKB1 | |
| SCHEMBL2908958 | 0.85 | ROCK2 (0.75) | CYP3A4KMT2ACYP2D6MYLKNFKB1 | |
| SCHEMBL14207926 | 0.84 | KMT2A (0.76) | CYP3A4KMT2ACYP2D6MYLKNFKB1 | |
| SCHEMBL3244492 | 0.83 | CYP3A4 (0.74) | CYP3A4KMT2ACYP2D6MYLKNFKB1 | |
| SCHEMBL10719519 | 0.83 | SMN1; SMN2 (0.80) | CYP3A4KMT2ACYP2D6MYLKNFKB1 | |
| SCHEMBL1271163 | 0.83 | ROCK1 (1.00) | CYP3A4KMT2ACYP2D6MYLKNFKB1 | |
| SCHEMBL16613226 | 0.83 | KMT2A (0.74) | CYP3A4KMT2ACYP2D6MYLKNFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 119 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4732908-A2 | CANCER TREATMENT USING COMBINATIONS OF ERK AND RAF INHIBITORS | Biomed Valley Discoveries, Inc. (US) | 2026-04-29 | — | — | EP | claimed |
| EP-4043017-B1 | CANCER TREATMENT USING COMBINATIONS OF ERK AND RAF INHIBITORS | BIOMED VALLEY DISCOVERIES INC (US) | 2026-01-28 | — | — | EP | claimed |
| EP-4512480-A2 | CANCER TREATMENTS USING COMBINATIONS OF CDK AND ERK INHIBITORS | Biomed Valley Discoveries, Inc. (US) | 2025-02-26 | — | — | EP | claimed |
| CN-116036278-B | Compositions and methods for treating cancers with atypical BRAF mutations | 生物医学谷探索股份有限公司 | 2024-12-17 | — | — | CN | claimed |
| EP-3082423-B1 | CANCER TREATMENTS USING COMBINATIONS OF CDK AND ERK INHIBITORS | BIOMED VALLEY DISCOVERIES INC (US) | 2024-12-11 | — | — | EP | claimed |
| EP-4389225-A2 | CANCER TREATMENTS USING COMBINATIONS OF TYPE 2 MEK AND ERK INHIBITORS | Biomed Valley Discoveries, Inc. (US) | 2024-06-26 | — | — | EP | claimed |
| EP-3082779-B1 | CANCER TREATMENTS USING COMBINATIONS OF TYPE 2 MEK AND ERK INHIBITORS | BIOMED VALLEY DISCOVERIES INC (US) | 2023-06-07 | — | — | EP | claimed |
| CN-116036278-A | Compositions and methods for treating cancers with atypical BRAF mutations | 生物医学谷探索股份有限公司 | 2023-05-02 | — | — | CN | claimed |
| EP-4062917-A1 | CANCER TREATMENTS USING COMBINATIONS OF PI3K/AKT PATHWAY AND ERK INHIBITORS | Biomed Valley Discoveries, Inc. (US) | 2022-09-28 | — | — | EP | claimed |
| CN-110799245-B | Compositions and methods for treating cancer with atypical BRAF mutations | 生物医学谷探索股份有限公司 | 2022-08-09 | — | — | CN | claimed |
| EP-3624896-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER WITH ATYPICAL BRAF MUTATIONS | Biomed Valley Discoveries, Inc. (US) | 2020-03-25 | — | — | EP | claimed |
| WO-2018213302-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER WITH ATYPICAL BRAF MUTATIONS | BIOMED VALLEY DISCOVERIES, INC. (US) | 2018-11-22 | — | — | WO | claimed |
| US-20180104228-A1 | METHODS AND COMPOSITIONS FOR TREATING NON-ERK MAPK PATHWAY INHIBITOR-RESISTANT CANCERS | BIOMED VALLEY DISCOVERIES, INC. | 2018-04-19 | — | — | US | claimed |
| US-20160367539-A1 | CANCER TREATMENTS USING COMBINATIONS OF TYPE 2 MEK AND ERK INHIBITORS | BIOMED VALLEY DISCOVERIES, INC. | 2016-12-22 | — | — | US | claimed |
| CN-106211755-A | Cancer treatment using a combination of ERK and RAF inhibitors | 生物医学谷探索股份有限公司 | 2016-12-07 | — | — | CN | claimed |
| US-20160317519-A1 | METHODS AND COMPOSITIONS FOR TREATING NON-ERK MAPK PATHWAY INHIBITOR-RESISTANT CANCERS | BIOMED VALLEY DISCOVERIES, INC. | 2016-11-03 | — | — | US | claimed |
| US-20160317538-A1 | CANCER TREATMENTS USING COMBINATIONS OF CDK AND ERK INHIBITORS | BIOMED VALLEY DISCOVERIES, INC. | 2016-11-03 | — | — | US | claimed |
| US-20160317517-A1 | CANCER TREATMENTS USING COMBINATIONS OF PI3K/AKT PATHWAY AND ERK INHIBITORS | BIOMED VALLEY DISCOVERIES, INC. | 2016-11-03 | — | — | US | claimed |
| US-20160310476-A1 | CANCER TREATMENT USING COMBINATIONS OF ERK AND RAF INHIBITORS | BIOMED VALLEY DISCOVERIES, INC. | 2016-10-27 | — | — | US | claimed |
| US-20160310477-A1 | CANCER TREATMENTS USING COMBINATIONS OF MEK TYPE 1 AND ERK INHIBITORS | BIOMED VALLEY DISCOVERIES, INC. | 2016-10-27 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180104228-A1 | METHODS AND COMPOSITIONS FOR TREATING NON-ERK MAPK PATHWAY INHIBITOR-RESISTANT CANCERS | MAP3K1, MAP3K2, MAP3K6 | CYP3A4 4609/4885KMT2A 1720/4885CYP2D6 4091/4885 |
| US-20160310476-A1 | CANCER TREATMENT USING COMBINATIONS OF ERK AND RAF INHIBITORS | BRAF, RAF1, MAPK3 | CYP3A4 3103/4885KMT2A 2462/4885CYP2D6 3223/4885 |
| US-20160367539-A1 | CANCER TREATMENTS USING COMBINATIONS OF TYPE 2 MEK AND ERK INHIBITORS | MAPK3, MAP3K2, MAP3K3 | CYP3A4 3226/4885KMT2A 1130/4885CYP2D6 3665/4885 |
| US-20160317538-A1 | CANCER TREATMENTS USING COMBINATIONS OF CDK AND ERK INHIBITORS | CDK3, CDK4, CDKL3 | CYP3A4 3413/4885KMT2A 626/4885CYP2D6 4006/4885 |
| US-20160310477-A1 | CANCER TREATMENTS USING COMBINATIONS OF MEK TYPE 1 AND ERK INHIBITORS | MAPK1, MAPK3, MAP3K1 | CYP3A4 3360/4885KMT2A 1681/4885CYP2D6 4093/4885 |
| US-20160317517-A1 | CANCER TREATMENTS USING COMBINATIONS OF PI3K/AKT PATHWAY AND ERK INHIBITORS | KRAS, BRAF, NRAS | CYP3A4 3657/4885KMT2A 2144/4885CYP2D6 4177/4885 |
| US-20160317519-A1 | METHODS AND COMPOSITIONS FOR TREATING NON-ERK MAPK PATHWAY INHIBITOR-RESISTANT CANCERS | MAP3K1, MAP3K2, MAP3K6 | CYP3A4 4609/4885KMT2A 1720/4885CYP2D6 4091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.